Table 5.
Potential predictors of the MDS-UPDRS3 total scores in 35 Parkinson patients.
| Β | 95% CI | ||
|---|---|---|---|
| Intercept | −4.10 | −46.71 | 38.51 |
| Akinetic-rigid PD vs. mixed PD | −4.13 | −14.40 | 6.14 |
| High education | −4.71 | −15.53 | 6.11 |
| Age [per 10 years] | 7.22 | 0.38 | 14.06 |
| Brain iron | |||
| R2*, globus pallidus [log 1/s] | 19.72 | −8.70 | 48.15 |
| R2*, substantia nigra [log 1/s] | 10.19 | −7.41 | 27.78 |
| Neurometabolites | |||
| Striatum | |||
| GABA | 7.71 | −21.54 | 36.95 |
| Glutamate and glutamine | −5.48 | −33.40 | 22.45 |
| Myo-inositol | 0.06 | −31.11 | 31.23 |
| Total creatine | 14.59 | −38.66 | 67.84 |
| Thalamus | |||
| GABA | −9.83 | −46.20 | 26.54 |
| Glutamate and glutamine | 1.18 | −28.92 | 31.28 |
| Myo-inositol | −29.00 | −58.21 | 0.21 |
| Total creatine | −5.49 | −75.39 | 64.42 |
Abbreviations: PD: Parkinson’s disease, GABA: γ-aminobutyric acid, R: relaxation rate, MDS-UPDRS3: Movement Disorder Society-Sponsored Revision of the Unified Parkinson Disease Rating Scale part III, β: estimate of regression coefficient (linear model) for potential predictors of motor dysfunction, in separate models for each neuroimaging variable adjusted for CSF content of the voxel (neurometabolites only), age (per 10 years), education (high, lower educational levels), CI: confidence interval (significant effects marked in bold and marginal effect marked in italic).